GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 51 [WO2022175752]
Compound class:
Synthetic organic
Comment: Voderdeucitinib is the INN for a (deuterated) Janus kinase inhibitor with anti-inflammatory potential (included in WHO INN proposed list 133, 10th July 2025). The chemical structure is claimed in patent WO2022175752 as a TYK2 inhibitor (TYK2 is a member of the Janus kinases family) [1]. The compound targets the TYK2 pseudokinase (JH2) domain, so is an allosteric inhibitor. The developer is SUDO biosciences who specialise in TYK2 inhibitor development, with 4 declared programmes in their pipeline, including two named inhibitors SUDO-550 (brain-penetrant, for neuroinflammatory diseases; phase 1) and SUDO-286 (topical, for immune-mediated dermatologic diseases; phase 1).
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 6-(cyclopropanecarbonylamino)-4-[(2,5-dimethyl-4H-pyrazolo[4,3-c]quinolin-6-yl)amino]-N-(trideuteriomethyl)pyridine-3-carboxamide |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 13591 | voderdeucitinib |
Synonyms ![]() |
| compound 51 [WO2022175752] |
Database Links ![]() |
|
| CAS Registry No. | 2824164-00-1 (source: WHO INN record) |
| GtoPdb PubChem SID | 518520693 |
| PubChem CID | 164944192 |
| Search Google for chemical match using the InChIKey | MQTVKOFFRJQEQS-FIBGUPNXSA-N |
| Search Google for chemicals with the same backbone | MQTVKOFFRJQEQS |
| Search PubMed clinical trials | voderdeucitinib |
| Search PubMed titles | voderdeucitinib |
| Search PubMed titles/abstracts | voderdeucitinib |
| UniChem Compound Search for chemical match using the InChIKey | MQTVKOFFRJQEQS-FIBGUPNXSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | MQTVKOFFRJQEQS-FIBGUPNXSA-N |